C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
AIMS: The aim of the present study was to compare the prognostic value of a novel and promising marker, copeptin, with B-type natriuretic peptide (BNP), and N-terminal pro-BNP (NT-proBNP), on death or a composite cardiovascular endpoint in patients who developed heart failure after an acute myocardial infarction (AMI). METHODS AND RESULTS: From a subset of 224 patients of the OPTIMAAL study, blood samples were drawn at a mean of 3 days after AMI when all patients had signs and/or symptoms of heart failure or a left ventricular ejection fraction <0.35. Endpoints of interest were mortality (primary endpoint of OPTIMAAL) and a composite cardiovascular endpoint, including death, MI, stroke, and/or resuscitated cardiac arrest. Mean age was 67 +/- 10 years, and mean follow-up was 33 +/- 7 months. Using univariable Cox proportional hazards survival analysis, higher levels of copeptin, BNP, and NT-proBNP were all significantly related to both mortality and the composite cardiovascular endpoint (all P < 0.01). In a multivariable Cox proportional hazards model, including all three biomarkers and other relevant covariates, a doubling of copeptin was related to a 1.83 (1.26-2.64) times increased risk of mortality (P < 0.0001) and a 1.35 (1.05-1.72) times increased risk of the composite cardiovascular endpoint (P = 0.018). Receiver operating characteristic curves indicated that copeptin [area under curve (AUC) 0.81] was a stronger predictor of mortality compared with both BNP (AUC 0.66; P = 0.0063 vs. copeptin) and NT-proBNP (AUC 0.67; P = 0.0016 vs. copeptin). Finally, changes of copeptin levels after 1 month significantly added prognostic information to the baseline value. CONCLUSION: Copeptin is a strong and novel marker for mortality and morbidity in patients with heart failure after AMI. In this population, the predictive value of copeptin was even stronger than BNP and NT-proBNP.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Plasma copeptin, a marker of vasopressin level, is elevated in myocardial infarction1 and predict prognosis in patients who developed heart failure after myocardial infarction.2”
From Plasma Copeptin and the Risk of Diabetes Mellitus (2010) · cites this paper as [2]
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Konstam, M. A. (2007) · JAMA · doi:10.1001/jama.297.12.1319 · Cited by 1,628
Francis, G. S., Benedict, C., Johnstone, D. E., Kirlin, P. C., Nicklas, J., Liang, C. S., Kubo, S. H., Rudin-Toretsky, E., & Yusuf, S. (1990) · Circulation · doi:10.1161/01.cir.82.5.1724 · Cited by 1,388 · cited 2×
“SBP [mean (+SD)] 124 (17) 125 (16) 124 (17) 125 (14) 122 (21) 0.”
Dickstein, K., & Kjekshus, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09895-1 · Cited by 1,203
Self-citationAssay for the Measurement of Copeptin, a Stable Peptide Derived from the Precursor of Vasopressin
Morgenthaler, N. G., Struck, J., Alonso, C., & Bergmann, A. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.060038 · Cited by 1,166 · cited 3×
“Diabetes [n (%)] 26 (12) 5 (9) 4 (8) 8 (15) 8 (15) 0.”
Self-citationPlasma brain natriuretic peptide concentration: impact of age and gender
Redfield, M. M., Rodeheffer, R. J., Jacobsen, S. J., Mahoney, D. W., Bailey, K. R., & Burnett, J. C. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02059-4 · Cited by 1,138 · cited 2×
“(3) In heart failure, angiotensin II levels are increased, even in the presence of ACE-inhibitors, and angiotensin II showed to increase AVP levels as well.”
BackgroundTsutamoto, T., Wada, A., Maeda, K., Hisanaga, T., Maeda, Y., Fukai, D., Ohnishi, M., Sugimoto, Y., & Kinoshita, M. (1997) · Circulation · doi:10.1161/01.cir.96.2.509 · Cited by 963 · cited 1×
“(1) Release of AVP in heart failure is mainly driven by a reduction in cardiac output, resulting in arterial underfilling, which activates the baroreceptors in the carotid sinus and the aortic arch.”
BackgroundRobertson, G. L., Mahr, E. A., Athar, S., & Sinha, T. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107423 · Cited by 787
Increased plasma arginine vasopressin levels in patients with congestive heart failure
Goldsmith, S. R., Francis, G. S., Cowley, A. W., Barry Levine, T., & Cohn, J. N. (1983) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(83)80040-0 · Cited by 484 · cited 1×
“73 m(2)) 72 (17) 78 (13) 78 (12) 75 (17) 61 (18) ,0.”
Cited by
Heart failure and kidney dysfunction: epidemiology, mechanisms and management
Schefold, J. C., Filippatos, G., Hasenfuss, G., Anker, S. D., & von Haehling, S. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.113 · Cited by 671
Self-citationPlasma Copeptin and the Risk of Diabetes Mellitus
Enhörning, S., Wang, T. J., Nilsson, P. M., Almgren, P., Hedblad, B., Berglund, G., Struck, J., Morgenthaler, N. G., Bergmann, A., Lindholm, E., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.909663 · Cited by 299
Self-citationDiagnostic markers of acute myocardial infarction
MYTHILI, S., & MALATHI, N. (2015) · Biomedical Reports · doi:10.3892/br.2015.500 · Cited by 249
Cahill, T. J., & Kharbanda, R. K. (2017) · World Journal of Cardiology · doi:10.4330/wjc.v9.i5.407 · Cited by 210
Copeptin: A Biomarker of Cardiovascular and Renal Function
Morgenthaler, N. G. (2010) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2010.00177.x · Cited by 181
Metadata
- Authors
- Voors, A. A., von Haehling, S., Anker, S. D., Hillege, H. L., Struck, J., Hartmann, O., Bergmann, A., Squire, I., van Veldhuisen, D. J., Dickstein, K., & for the OPTIMAAL Investigators
- Affiliations
- University Medical Center Groningen (NL)
- Charité – Universitätsmedizin Berlin (DE)
- University of Leicester (GB)
- Stavanger University Hospital (NO)
- Corresponding author
- Voors, A. A.
- ORCID
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-04-03
- Volume
- 30
- Issue
- 10
- Pages
- 1187-1194
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W1973435154
- Cited by
- 222
- References
- 27
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 2 · 2022: 9 · 2021: 15 · 2020: 16 · 2019: 11 · 2018: 11 · 2017: 14 · 2016: 16 · 2015: 25 · 2014: 12 · 2013: 20 · 2012: 19
- FWCI
- 12.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- copeptin, post-infarction heart failure, prognostic factors, brain natriuretic peptide, NT-proBNP, mortality, left ventricular ejection fraction, cardiac biomarkers
- MeSH terms
- Aged, Arginine Vasopressin, Enzyme-Linked Immunosorbent Assay, Female, Glycopeptides, Heart Failure, Humans, Male, Middle Aged, Myocardial Infarction, Peptide Fragments, Prognosis, Sensitivity and Specificity, Stroke Volume, Time Factors, Biomarkers, Natriuretic Peptide, Brain, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. https://app.cochat.ai/papers/10.1093/eurheartj/ehp098
- The paper
- Voors, A. A., von Haehling, S., Anker, S. D., Hillege, H. L., Struck, J., Hartmann, O., Bergmann, A., Squire, I., van Veldhuisen, D. J., Dickstein, K., & for the OPTIMAAL Investigators. (2009). C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. European Heart Journal. https://doi.org/10.1093/eurheartj/ehp098
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.